The D-Health Trial: A randomized trial of vitamin D for prevention of mortality and cancer

Neale, Rachel E.; Armstrong, Bruce K.; Baxter, Catherine; Romero, Briony Duarte; Ebeling, Peter R.; English, Dallas R.; Kimlin, Michael G.; McLeod, Donald S A; O’Connell, Rachel; Pols, Jolieke C. van der; Venn, Alison; Webb, Penelope M.; Whiteman, David C.; Wockner, Leesa

doi:10.1016/j.cct.2016.04.005

Cited by 109 publications

(77 citation statements)

References 24 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…With regard to vitamin D, the benefit of supplementation remains unclear and the need for adequately powered studies in well‐defined populations is required . The outcomes of ongoing major randomized controlled trials will be informative . There may be scope to utilize vitamin D status as a biomarker for diabetes risk, with which to identify older adults for lifestyle interventions based on healthy eating, physical activity and exercise (indoors and outdoors) rather than vitamin D supplementation.…”

Section: Discussionmentioning

confidence: 99%

“…40,47,48 The outcomes of ongoing major randomized controlled trials will be informative. 49,50 There may be scope to utilize vitamin D status as a biomarker for diabetes risk, with which to identify older adults for lifestyle interventions based on healthy eating, physical activity and exercise (indoors and outdoors) rather than vitamin D supplementation.…”

Section: Mendelian Randomization For Vitamin D-related Polymorphismmentioning

confidence: 99%

See 1 more Smart Citation

Differential associations of ferritin and 25‐hydroxyvitamin D with fasting glucose and diabetes risk in community dwelling older men

Carrivick

Alfonso

Golledge

et al. 2019

Diabetes Metabolism Res

View full text Add to dashboard Cite

Aims We examined associations of ferritin and 25‐hydroxyvitamin D with fasting glucose and prevalent diabetes in older men. Methods Cross‐sectional analysis of 4153 community‐dwelling men aged 70 to 89 years in Western Australia. Plasma ferritin, 25‐hydroxyvitamin D, and glucose were assayed. Diabetes was ascertained from self‐report, medications, and fasting glucose. Results There were 577 men with diabetes (13.9%). In the whole cohort, ferritin was associated with fasting glucose (0.051 mmol/L per 1 SD increase in ferritin, P = .006) and 25‐hydroxyvitamin D was inversely associated (−0.085 mmol/L per 1 SD, P < .001). Ferritin was not associated with prevalent diabetes (highest vs. lowest quartile; >225 vs <66 μg/L: adjusted odds ratio [OR] 0.97, 95% confidence interval [CI], 0.74‐1.27, P = .83). Higher vitamin D was associated with decreased odds of prevalent diabetes (highest vs lowest quartile; >82 nmol/L vs <53 nmol/L: OR = 0.57, 95% CI = 0.43‐0.75, P < .001). There was no interaction between ferritin and vitamin D on diabetes risk. Conclusions In older men, ferritin is associated with fasting glucose but not prevalent diabetes. Higher 25‐hydroxyvitamin D concentrations are independently associated with lower fasting glucose and reduced risk of diabetes. Clinical trials are required to determine whether interventions, which raise vitamin D concentrations, would reduce incidence of diabetes in this expanding demographic group.

show abstract

Section: Discussionmentioning

confidence: 99%

Section: Mendelian Randomization For Vitamin D-related Polymorphismmentioning

confidence: 99%

Differential associations of ferritin and 25‐hydroxyvitamin D with fasting glucose and diabetes risk in community dwelling older men

Carrivick

Alfonso

Golledge

et al. 2019

Diabetes Metabolism Res

View full text Add to dashboard Cite

show abstract

“…In community-based trials (e.g. VITAL, D-HEALTH) (111,112), the study is conducted 'by mail' and participants are not evaluated in-person. Study pills are mailed to participants living in the community and outcomes are self-reported based on surveys or through search of Electronic Health Records.…”

Section: Ongoing Rcts With Vitamin D Supplementationmentioning

confidence: 99%

“…Many trials (e.g., VITAL, D-HEALTH) (111,112,115,116,117,118,119) will conduct analyses for a very large number of secondary outcomes, and the possibility of false-negative results due to multiplicity of testing is also a real concern. Therefore, there is a need for reproducibility of results before any positive finding is widely accepted.…”

Section: Ongoing Rcts With Vitamin D Supplementationmentioning

confidence: 99%

MANAGEMENT OF ENDOCRINE DISEASE: Therapeutics of vitamin D

Ebeling

Adler

Jones

et al. 2018

European Journal of Endocrinology

View full text Add to dashboard Cite

show abstract

“…There are multiple large-scale vitamin D supplementation trials currently underway. The largest of which are the VITamin D and OmegA-3 TriaL (VITAL), a placebo-controlled, double-blind 2×2 factorial trial of over 25,875 multi-ethnic participants randomized to 2,000 IU/day of vitamin D 3 and omega-3 fatty acid supplements for 5 years [82], and the D-Health Trial, a placebo-controlled trial with 21,315 participants randomized to 60,000 IU/month of vitamin D 3 for 5 years [83]. …”

Section: Randomized Controlled Trials (Rct) Of Vitamin D and Cvd Outcmentioning

confidence: 99%

Vitamin D, Calcium, and Cardiovascular Disease: A“D”vantageous or “D”etrimental? An Era of Uncertainty

Chin

Appel

Michos

2017

Curr Atheroscler Rep

View full text Add to dashboard Cite

While the function of vitamin D in regulating calcium homeostasis is well established, there has been growing interest in its role in the prevention of numerous chronic diseases, including cardiovascular disease (CVD). There is mounting epidemiological evidence suggesting that vitamin D deficiency is linked to increased CVD risk. However, the results of previous vitamin D supplementation trials have yielded mixed results in regards to cardiovascular health, and the results of on-going large-scale randomized controlled trials are not yet available. Further complicating the issue, calcium supplementation, which is often prescribed concurrently with vitamin D, has been associated with increased CVD risk in some (but not all) studies. Thus, it is currently unclear whether vitamin D supplements, particularly for those that are deficient, can help prevent the development of CVD. In addition, there has not been uniform consensus regarding the threshold of 25-hydroxyvitamin D levels that constitutes “sufficiency” across organizational guidelines. This review will provide an update on the most recent evidence regarding the effects of vitamin D and calcium supplements on CVD clinical outcomes, summarize ongoing vitamin D trials, and discuss the current but remarkably disparate recommendations regarding vitamin D deficiency screening and supplementation.

show abstract

The D-Health Trial: A randomized trial of vitamin D for prevention of mortality and cancer

Abstract: Observational data cannot be considered sufficient to support interventions delivered at a population level. Large-scale randomized trials such as the D-Health Trial are needed to inform public health policy and practice.

Cited by 109 publications

References 24 publications

Differential associations of ferritin and 25‐hydroxyvitamin D with fasting glucose and diabetes risk in community dwelling older men

Differential associations of ferritin and 25‐hydroxyvitamin D with fasting glucose and diabetes risk in community dwelling older men

MANAGEMENT OF ENDOCRINE DISEASE: Therapeutics of vitamin D

Vitamin D, Calcium, and Cardiovascular Disease: A“D”vantageous or “D”etrimental? An Era of Uncertainty

Contact Info

Product

Resources

About